The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment an…

Moderate Hepatic Impairment

~Estimated

~$10 – $7,500

AstraZenecaNCT07343960

Phase 1

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment

The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compare…

Hepatic ImpairmentModerate Hepatic Impairment

~Estimated

~$10 – $7,500

ExelixisNCT06962332